IMB-101 (IMBiologics)

N/A

Report date: 2026/03/07 20:00:27

Base Information

Drug NameIMB-101 (IMBiologics)
Drug Alias NameHDM-3019IMB-101 (IMBiologics)IMB101 (IMBiologics)HDM3019NAV-240
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Tumor necrosis factor αTumor necrosis factor ligand superfamily member 4 inhibitors
TargetsTumor necrosis factor ligand superfamily member 4Tumor necrosis factor α
Therapy Area/IndicationsArthritis, RheumatoidHidradenitis Suppurativa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesIMBiologics Corp
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNavigator Medicines IncNavigator MedicinesIMBiologics Corp +[4] 
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidHidradenitis Suppurativa
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A